Major Investors & Financial Advisor Resell 9.6M Shares, Company Receives No Proceeds Amidst 'Going Concern' Warning

summarizeSummary

Lakewood-Amedex Biotherapeutics Inc. filed a final prospectus for the resale of 9.6 million shares by major investors and its financial advisor, which could result in over 67% dilution for existing shareholders, with no proceeds going to the company, amidst a 'going concern' warning.

check_boxKey Events

• Massive Potential Dilution

  A final prospectus was filed for the resale of 9,647,726 shares of common stock, representing approximately 67.37% of the current outstanding shares.

• No Proceeds to Company

  The company will not receive any funds from the sale of these shares, despite facing a 'going concern' warning from its auditors.

• Major Selling Stockholders

  The shares are being resold by Shakawe Capital LLC (a major investor from a Series C Preferred Stock financing) and Dawson James Securities, Inc. (the company's financial advisor).

• Financial Distress Confirmed

  The company's financial statements include an explanatory paragraph from auditors expressing 'substantial doubt about our ability to continue as a going concern'.

auto_awesomeAnalysis

This final prospectus enables major investors and the company's financial advisor to resell 9.6 million shares, representing a massive 67% potential dilution for existing shareholders. The company will receive no proceeds from these sales, which is a critical negative given the explicit 'going concern' warning from auditors. The fact that key stakeholders are selling shares, some convertible at a deep discount to current market prices, signals severe financial distress and a lack of confidence, placing significant downward pressure on the stock, which is already trading near its 52-week low.